Log in

Amgen Stock Price, Forecast & Analysis (NASDAQ:AMGN)

$221.31
+0.61 (+0.28 %)
(As of 11/13/2019 08:00 AM ET)
Today's Range
$219.87
Now: $221.31
$225.26
50-Day Range
$189.09
MA: $204.19
$221.29
52-Week Range
$166.30
Now: $221.31
$225.26
Volume2.70 million shs
Average Volume2.90 million shs
Market Capitalization$131.50 billion
P/E Ratio15.37
Dividend Yield2.63%
Beta1.09
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AMGN
CUSIP03116210
Phone805-447-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.75 billion
Cash Flow$18.10 per share
Book Value$19.62 per share

Profitability

Net Income$8.39 billion

Miscellaneous

Employees21,500
Market Cap$131.50 billion
Next Earnings Date2/4/2020 (Estimated)
OptionableOptionable

Receive AMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.


Amgen (NASDAQ:AMGN) Frequently Asked Questions

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen declared a quarterly dividend on Tuesday, October 22nd. Stockholders of record on Friday, November 15th will be paid a dividend of $1.45 per share on Friday, December 6th. This represents a $5.80 dividend on an annualized basis and a dividend yield of 2.62%. The ex-dividend date is Thursday, November 14th. View Amgen's Dividend History.

How will Amgen's stock buyback program work?

Amgen announced that its Board of Directors has authorized a share buyback program on Friday, February 2nd 2018, which permits the company to repurchase $10,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's board believes its shares are undervalued.

How were Amgen's earnings last quarter?

Amgen, Inc. (NASDAQ:AMGN) released its earnings results on Tuesday, October, 29th. The medical research company reported $3.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.53 by $0.13. The medical research company earned $5.74 billion during the quarter, compared to the consensus estimate of $5.63 billion. Amgen had a net margin of 34.48% and a return on equity of 80.26%. Amgen's revenue for the quarter was down 2.8% on a year-over-year basis. During the same period in the prior year, the business earned $3.69 EPS. View Amgen's Earnings History.

When is Amgen's next earnings date?

Amgen is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Amgen.

What guidance has Amgen issued on next quarter's earnings?

Amgen updated its FY19 earnings guidance on Tuesday, October, 29th. The company provided earnings per share guidance of $14.20-14.45 for the period, compared to the Thomson Reuters consensus estimate of $14.40. The company issued revenue guidance of $22.8-23.0 billion, compared to the consensus revenue estimate of $22.87 billion.

What price target have analysts set for AMGN?

21 brokers have issued 1 year price targets for Amgen's stock. Their forecasts range from $195.00 to $256.00. On average, they anticipate Amgen's share price to reach $221.72 in the next year. This suggests a possible upside of 0.2% from the stock's current price. View Analyst Price Targets for Amgen.

What is the consensus analysts' recommendation for Amgen?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 9 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amgen.

What are Wall Street analysts saying about Amgen stock?

Here are some recent quotes from research analysts about Amgen stock:
  • 1. William Blair analysts commented, "We ultimately view the deal as positive for Amgen and a good fit for management’s strategy given the low-risk nature of the deal and immediate accretion." (8/30/2019)
  • 2. Evercore ISI analysts commented, "We used a discount rate which is a function of cost of equity and cost of debt. Terminal growth rate estimates were used to derive future cash flows." (8/11/2019)
  • 3. According to Zacks Investment Research, "While Amgen’s newer drugs — Prolia, Xgeva, Blincyto, Kyprolis — will drive sales, biosimilar and brand competition faced by its legacy drugs will create pressure on the top line in 2019. Meanwhile, uptake of key drug, Repatha has been slow due to payer restrictions. However, Amgen is progressing well with its pipeline and approval of Aimovig was a huge boost. In the past five years, Amgen has launched nine products, including two in new therapeutic areas. Amgen boasts a strong biosimilars pipeline, which could be an important long-term growth driver for the company. Amgen’s restructuring plan is making it leaner and more cost efficient. Lower taxes and share buybacks should provide some support to the bottom line. Amgen’s shares have underperformed the industry this year so far. Estimates have declined lightly ahead of the Q1 earnings release. Amgen has a positive record of earnings surprises in recent quarters." (4/15/2019)
  • 4. Mizuho analysts commented, "We think the peak sales potential of Vascepa is underappreciated. Therefore, upward earnings revisions to levels not reflected in FactSet consensus expectations should drive AMRN shares higher. Valuation Summary We continue to use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $35." (4/12/2019)
  • 5. Cantor Fitzgerald analysts commented, ". We Reiterate our Neutral rating and $221 Price Target. We are attending the AACR (cancer research meeting) in Atlanta. Amgen presented its preclinical data for 24-minute session. The company’s molecule is targeting the KRAS p.G12C mutation and is a covalent inhibitor. The presentation explained how it identified a unique groove formed by rotation of an adjacent histidine residue (H95). An inactive form of KRAS reveals a small pocket P2 in GDP-KRAS, which is adjacent to cys12. The molecule binds to P2 and H95 and is expected to be dosed orally once daily. 510 has single-digit nanomolar potency and is 1,000x more selective to other KRAS mutants." (4/1/2019)

Has Amgen been receiving favorable news coverage?

Media stories about AMGN stock have trended very negative recently, according to InfoTrie. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Amgen earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Amgen.

Are investors shorting Amgen?

Amgen saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 9,180,000 shares, an increase of 7.1% from the September 30th total of 8,570,000 shares. Based on an average trading volume of 2,890,000 shares, the short-interest ratio is currently 3.2 days. Approximately 1.5% of the company's shares are short sold. View Amgen's Current Options Chain.

Who are some of Amgen's key competitors?

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), Alibaba Group (BABA), Intel (INTC), Walt Disney (DIS), NVIDIA (NVDA), Cisco Systems (CSCO), Gilead Sciences (GILD), AT&T (T), JPMorgan Chase & Co. (JPM) and Pfizer (PFE).

Who are Amgen's key executives?

Amgen's management team includes the folowing people:
  • Mr. Robert A. Bradway, Chairman, CEO & Pres (Age 56)
  • Mr. David W. Meline, Exec. VP & CFO (Age 62)
  • Mr. Jonathan P. Graham, Sr. VP, Gen. Counsel & Sec. (Age 58)
  • Dr. David M. Reese M.D., Exec. VP of R&D (Age 56)
  • Mr. Murdo Gordon, Exec. VP of Global Commercial Operations (Age 52)

Who are Amgen's major shareholders?

Amgen's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.40%), California Public Employees Retirement System (0.26%), Coho Partners Ltd. (0.18%), First Trust Advisors LP (0.18%), Beutel Goodman & Co Ltd. (0.18%) and Rhumbline Advisers (0.18%). Company insiders that own Amgen stock include Cynthia M Patton, R Sanders Williams, Ronald D Sugar, Sean E Harper and Tyler Jacks. View Institutional Ownership Trends for Amgen.

Which institutional investors are selling Amgen stock?

AMGN stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., First Trust Advisors LP, Sawgrass Asset Management LLC, Candriam Luxembourg S.C.A., Sumitomo Mitsui Trust Holdings Inc., Teacher Retirement System of Texas, Russell Investments Group Ltd. and Gateway Investment Advisers LLC. Company insiders that have sold Amgen company stock in the last year include Cynthia M Patton, R Sanders Williams, Ronald D Sugar and Tyler Jacks. View Insider Buying and Selling for Amgen.

Which institutional investors are buying Amgen stock?

AMGN stock was purchased by a variety of institutional investors in the last quarter, including Railway Pension Investments Ltd, California Public Employees Retirement System, State of Tennessee Treasury Department, State of New Jersey Common Pension Fund D, Wedge Capital Management L L P NC, Bartlett & Co. LLC, Handelsbanken Fonder AB and Calamos Advisors LLC. View Insider Buying and Selling for Amgen.

How do I buy shares of Amgen?

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $221.31.

How big of a company is Amgen?

Amgen has a market capitalization of $131.50 billion and generates $23.75 billion in revenue each year. The medical research company earns $8.39 billion in net income (profit) each year or $14.40 on an earnings per share basis. Amgen employs 21,500 workers across the globe.View Additional Information About Amgen.

What is Amgen's official website?

The official website for Amgen is http://www.amgen.com/.

How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]


MarketBeat Community Rating for Amgen (NASDAQ AMGN)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  1,336 (Vote Outperform)
Underperform Votes:  868 (Vote Underperform)
Total Votes:  2,204
MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe AMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel